Last 7.25 INR
Change Today 0.00 / 0.00%
Volume 6.5K
PDL On Other Exchanges
Symbol
Exchange
Natl India
As of 1:28 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

parabolic drugs ltd (PDL) Snapshot

Open
7.25
Previous Close
7.25
Day High
7.45
Day Low
7.10
52 Week High
07/3/14 - 9.60
52 Week Low
08/7/13 - 3.39
Market Cap
448.7M
Average Volume 10 Days
66.1K
EPS TTM
8.27
Shares Outstanding
61.9M
EX-Date
09/24/12
P/E TM
0.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for PARABOLIC DRUGS LTD (PDL)

Related News

No related news articles were found.

parabolic drugs ltd (PDL) Related Businessweek News

No Related Businessweek News Found

parabolic drugs ltd (PDL) Details

Parabolic Drugs Limited develops and manufactures active pharmaceutical ingredients (API) and API intermediates primarily in India. The company offers cephalosporin and semi synthetic penicillin APIs in oral and sterile forms, intermediates, potent active ingredients, and herbal APIs, as well as non-antibiotic APIs for the therapeutic areas, such as cardiovascular, NSAID, anti-hypertensive, and osteoporosis. It also provides custom research and manufacturing services to pharma companies, including research and development, and manufacturing services for NCE and generics; IPR support for process design and infringement guidance; and QA, QC, and regulatory support for meeting global quality and documentation requirements. The company markets its products in approximately 55 countries, primarily including the Middle East, the United Kingdom, Africa, China, Korea, Japan, the European Union, Latin America, the United States, and ASEAN. Parabolic Drugs Limited was founded in 1996 and is headquartered in Chandigarh, India.

1,011 Employees
Last Reported Date: 07/20/10
Founded in 1996

parabolic drugs ltd (PDL) Top Compensated Officers

Chairman, Managing Director, Member of Audit ...
Total Annual Compensation: 9.6M
Whole Time Director
Total Annual Compensation: 8.4M
Compensation as of Fiscal Year 2013.

parabolic drugs ltd (PDL) Key Developments

Parabolic Drugs Ltd. Reports Audited Standalone Earnings Results for the Fourth Quarter and Full Year and Consolidated Earnings Results for the Year Ended March 31, 2014

Parabolic Drugs Ltd. reported audited standalone earnings results for the fourth quarter and full year and consolidated earnings results for the year ended March 31, 2014. For the quarter, the company’s net sales/income from operations (net of excise duty) was INR 1.1618 billion compared to INR 0.5936 billion a year ago. Loss from operations before other income, finance cost and exceptional items were INR 0.9411 billion compared to INR 1.3929 billion a year ago. Loss from ordinary activities before tax was INR 1.1766 billion compared to INR 1.5600 billion a year ago. Net loss was INR 0.6101 billion or INR 9.86 per basic and diluted share before and after extraordinary items compared to INR 0.9867 billion or INR 15.94 per basic and diluted share before and after extraordinary items for the same period a year ago. For the year, the company’s net sales/income from operations (net of excise duty) was INR 4.3038 billion compared to INR 7.6136 billion a year ago. Loss from operations before other income, finance cost and exceptional items were INR 1.3695 billion compared to INR 1.2524 billion a year ago. Loss from ordinary activities before tax was INR 2.2002 billion compared to INR 1.9502 billion a year ago. Net loss was INR 1.3174 billion or INR 21.29 per basic and diluted share before and after extraordinary items compared to INR 1.3976 billion or INR 22.58 per basic and diluted share before and after extraordinary items for the same period a year ago. For the year, on consolidated basis, the company’s net sales/income from operations (net of excise duty) was INR 4.3037 billion compared to INR 7.6244 billion a year ago. Loss from operations before other income, finance cost and exceptional items were INR 1.3839 billion compared to INR 1.3036 billion a year ago. Loss from ordinary activities before tax was INR 2.2209 billion compared to INR 2.0066 billion a year ago. Net loss was INR 1.3381 billion or INR 21.62 per basic and diluted share before and after extraordinary items compared to INR 1.4449 billion or INR 23.35 per basic and diluted share before and after extraordinary items for the same period a year ago.

Parabolic Drugs Ltd., Board Meeting, May 30, 2014

Parabolic Drugs Ltd., Board Meeting, May 30, 2014. Agenda: To approve audited results.

Parabolic Drugs Ltd. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

Parabolic Drugs Ltd. announced unaudited earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, the company reported net sales of INR 1,080.7 million compared with INR 1,503.2 million for the same period a year ago. Loss from operation before other income, finance cost and exceptional items was INR 154.7 million compared with INR 64.4 million for the same period a year ago. Loss from ordinary activities before tax was INR 354.0 million compared with INR 245.9 million for the same period a year ago. Net loss was INR 244.6 million or INR 3.95 per basic and diluted share before and after extraordinary items compared with INR 255.9 million or INR 4.14 per basic and diluted share before and after extraordinary items for the same period a year ago. For the nine months, the company reported net sales of INR 3,183.3 million compared with INR 7,048.6 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 428.4 million compared with profit from operation before other income, finance cost and exceptional items of INR 140.6 million for the same period a year ago. Loss from ordinary activities before tax was INR 1,023.6 million compared with INR 390.1 million for the same period a year ago. Net loss was INR 707.3 million or INR 11.43 per basic and diluted share before and after extraordinary items compared with INR 410.8 million or INR 6.64 per basic and diluted share before and after extraordinary items for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDL:IN 7.25 INR 0.00

PDL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PDL.
View Industry Companies
 

Industry Analysis

PDL

Industry Average

Valuation PDL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PARABOLIC DRUGS LTD, please visit www.parabolicdrugs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.